Your browser doesn't support javascript.
loading
Runx1 negatively regulates inflammatory cytokine production by neutrophils in response to Toll-like receptor signaling.
Bellissimo, Dana C; Chen, Chia-Hui; Zhu, Qin; Bagga, Sumedha; Lee, Chung-Tsai; He, Bing; Wertheim, Gerald B; Jordan, Martha; Tan, Kai; Worthen, G Scott; Gilliland, D Gary; Speck, Nancy A.
Affiliation
  • Bellissimo DC; Department of Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Chen CH; Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA.
  • Zhu Q; Graduate Group in Genomics and Computational Biology.
  • Bagga S; Department of Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Lee CT; Department of Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • He B; Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA.
  • Wertheim GB; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, and.
  • Jordan M; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, and.
  • Tan K; Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA.
  • Worthen GS; Graduate Group in Genomics and Computational Biology.
  • Gilliland DG; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Speck NA; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Blood Adv ; 4(6): 1145-1158, 2020 03 24.
Article in En | MEDLINE | ID: mdl-32208490
RUNX1 is frequently mutated in myeloid and lymphoid malignancies. It has been shown to negatively regulate Toll-like receptor 4 (TLR4) signaling through nuclear factor κB (NF-κB) in lung epithelial cells. Here we show that RUNX1 regulates TLR1/2 and TLR4 signaling and inflammatory cytokine production by neutrophils. Hematopoietic-specific RUNX1 loss increased the production of proinflammatory mediators, including tumor necrosis factor-α (TNF-α), by bone marrow neutrophils in response to TLR1/2 and TLR4 agonists. Hematopoietic RUNX1 loss also resulted in profound damage to the lung parenchyma following inhalation of the TLR4 ligand lipopolysaccharide (LPS). However, neutrophils with neutrophil-specific RUNX1 loss lacked the inflammatory phenotype caused by pan-hematopoietic RUNX1 loss, indicating that dysregulated TLR4 signaling is not due to loss of RUNX1 in neutrophils per se. Rather, single-cell RNA sequencing indicates the dysregulation originates in a neutrophil precursor. Enhanced inflammatory cytokine production by neutrophils following pan-hematopoietic RUNX1 loss correlated with increased degradation of the inhibitor of NF-κB signaling, and RUNX1-deficient neutrophils displayed broad transcriptional upregulation of many of the core components of the TLR4 signaling pathway. Hence, early, pan-hematopoietic RUNX1 loss de-represses an innate immune signaling transcriptional program that is maintained in terminally differentiated neutrophils, resulting in their hyperinflammatory state. We hypothesize that inflammatory cytokine production by neutrophils may contribute to leukemia associated with inherited RUNX1 mutations.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Core Binding Factor Alpha 2 Subunit / Neutrophils Language: En Journal: Blood Adv Year: 2020 Document type: Article Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Core Binding Factor Alpha 2 Subunit / Neutrophils Language: En Journal: Blood Adv Year: 2020 Document type: Article Country of publication: United States